A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts Liver Metastases

Yu Wen Tien, Hsun-Chuan Kuo, Be-Ing Ho, Ming-Chu Chang, Yu-Ting Chang, Mei-Fang Cheng, Huai-Lu Chen, Ting-Yung Liang, Chien-Fang Wang, Chia-Yi Huang, Jin-Yuh Shew, Ying Chih Chang, Eva Yhp Lee, Wen-Hwa Lee, Yu Wen Tien, Hsun-Chuan Kuo, Be-Ing Ho, Ming-Chu Chang, Yu-Ting Chang, Mei-Fang Cheng, Huai-Lu Chen, Ting-Yung Liang, Chien-Fang Wang, Chia-Yi Huang, Jin-Yuh Shew, Ying Chih Chang, Eva Yhp Lee, Wen-Hwa Lee

Abstract

Circulating tumor cells (CTCs) released from a periampullary or pancreatic cancer can be more frequently detected in the portal than the systemic circulation and potentially can be used to identify patients with liver micrometastases. Aims of this study is to determine if CTCs count in portal venous blood of patients with nonmetastatic periampullary or pancreatic adenocarcinoma can be used as a predictor for subsequent liver metastases. CTCs were quantified in portal and peripheral venous blood samples collected simultaneously during pancreaticoduodenectomy in patients with presumed periampullary or pancreatic adenocarcinoma without image-discernible metastasis. Postoperatively patients were monitored for liver metastasis by abdominal magnetic resonance imaging or computed tomography every 3 months for 1 year. Sixty patients with a pathological diagnosis of periampullary or pancreatic adenocarcinoma were included in the study. Multivariate analysis indicated that portal CTC count was a significant predictor for liver metastases within 6 months after surgery. Eleven of 13 patients with a high portal CTCs count (defined as >112 CMx Platform estimated CTCs in 2 mL blood) developed liver metastases within 6 months after surgery. In contrast, only 6 of 47 patients with a low portal CTC count developed liver metastases (P < 0.0001). A value of 112 CMx Platform estimated CTCs had 64.7% sensitivity and 95.4% specificity to predict liver metastases within 6 months after surgery. We concluded that a high CTC count in portal venous blood collected during pancreaticoduodenectomy in patients with periampullary or pancreatic adenocarcinoma without metastases detected by currently available imaging tools is a significant predictor for liver metastases within 6 months after surgery.

Conflict of interest statement

The remaining authors have no conflicts of interest to disclose.

References

    1. Mittal R, Kowal C, Starzl T, et al. Accuracy of computed tomography in determining hepatic tumor size in patients receiving liver transplantation or resection. J Clin Oncol 1984; 2:637–642.
    1. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006; 238:405–422.
    1. Mizuno N, Kato Y, Izumi Y, et al. Importance of hepatic first-pass removal in metastasis of colon carcinoma cells. J Hepatol 1998; 8:865–877.
    1. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10:6897–6904.
    1. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331:1559–1564.
    1. Fidler IJ. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 1970; 45:773–782.
    1. Rahbari NN, Bork U, Kircher A, et al. Compartmental differences of circulating tumor cells in colorectal cancer. Ann Surg Oncol 2012; 19:2195–2202.
    1. Wu JC, Tseng PY, Tsai WS, et al. Antibody conjugated supported lipid bilayer for capturing and purification of viable tumor cells in blood for subsequent cell culture. Biomaterials 2013; 34:5191–5199.
    1. Lai JM, Shao HJ, Wu JC, et al. Efficient elusion of viable adhesive cells from a microfluidic system by air foam. Biomicrofluidics 2014; 8:052001.
    1. Yee T. W. (2014). VGAM: Vector generalized linear and additive models. R package, version 0.9-4 (URL: ).
    1. Yee TW, Wild CJ. Vector generalized additive models. J Roy Stat Soc B Met 1996; 58:481–493.
    1. Catenacci DVT, Chapman CG, Xu P, et al. Acqusition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound. Gastroenterology 2015; 149:1794–1803.
    1. Thakrar PD, Madoff DC. Preoperative portal vein embolization: an approach to improve the safety of major hepatic resection. Semin Roentgenol 2011; 46:142–153.
    1. Baccelli I, Schneeweiss A, Riethdrof S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31:539–545.
    1. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339:580–584.
    1. Hodgkinson CL, Morrow CJ, Metcalf RL, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014; 20:897–903.
    1. Rao CG, Chianese D, Doyle GV, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005; 27:49–57.
    1. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148:349–361.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다